Ivonescimab is named as a drug or biological intervention in 27 clinical trials in our China, USA, UK and Ireland trial registers, 19 of which are recruiting. Lead sponsors include Summit Therapeutics (2), Akeso (2) and Sichuan University (2). Registered phases: Phase 2, Phase 1/2, Phase 3, Phase 1 and Observational. Conditions studied include Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Pancreatic Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non-Small Cell Lung Cancer | 4 |
| Head and Neck Squamous Cell Carcinoma | 3 |
| Pancreatic Cancer | 2 |
| Non Small Cell Lung Cancer | 2 |
| Metastatic Colorectal Cancer (CRC) | 1 |
| Advanced Solid Tumors | 1 |
| Metastatic Solid Tumors | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
| NSCLC | 1 |
| Biliary Tract Cancer | 1 |
| Breast Cancer | 1 |
| Small Cell Lung Cancer | 1 |
| Advanced Malignant Tumors | 1 |
| Advanced Non-small Cell Lung Cancer | 1 |
| Metastatic Breast Cancer ( HER2 Negative) | 1 |
| ctDNA | 1 |
| Gastric Cancer | 1 |
| RCT | 1 |
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| Colorectal Cancer | 1 |
| Head and Neck Squamous Cell Carcinoma HNSCC | 1 |
| Colorectal Liver Metastases | 1 |
| LOCALLY ADVANCED CERVICAL CANCERS | 1 |
| Neoadjuvant Therapy | 1 |
| PD-1 Inhibitors | 1 |
| Immunotherapy | 1 |
| Immune Checkpoint Inhibitors (ICIs) | 1 |
| Rectal Cancer | 1 |
| Radiation | 1 |
| AK112 | 1 |
| NSCLC (Advanced Non-small Cell Lung Cancer) | 1 |
| SCLC, Recurrent | 1 |
| Lead sponsor | Trials |
|---|---|
| Summit Therapeutics | 2 |
| Akeso | 2 |
| Sichuan University | 2 |
| Fudan University | 2 |
| Sun Yat-sen University | 2 |
| Shandong Cancer Hospital and Institute | 2 |
| Revolution Medicines, Inc. | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Shanghai JMT-Bio Inc. | 1 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 1 |
| Peking Union Medical College | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Women's Hospital School Of Medicine Zhejiang University | 1 |
| Guangdong Association of Clinical Trials | 1 |
| Peking University People's Hospital | 1 |
| Second Xiangya Hospital of Central South University | 1 |
| Zhejiang Cancer Hospital | 1 |
| Lei Liu | 1 |
| Shaodong Hong | 1 |
| West China Hospital | 1 |
| Register | Ivonescimab trials |
|---|---|
| Clinical trials in China | 26 |
| Clinical trials in USA | 3 |
| Clinical trials in UK | 2 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ivonescimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ivonescimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.